Vectura fails key asthma test sending share price sharply lower
Shares in pharmaceutical business Vectura (VEC) fell sharply after its severe asthma treatment failed to prove effective versus placebo in Phase III trials.Vectura has been working on the VR475 treatment for several years, having...
26 November 2018